Literature DB >> 21233984

Monoamine oxidase inhibitors: clinical review.

R A Remick, C Froese.   

Abstract

Monoamine oxidase inhibitors (MAOIs) are effective antidepressant agents. They are increasingly and effectively used in a number of other psychiatric and non-psychiatric medical syndromes. Their potential for serious toxicity (i.e., hypertensive reaction) is far less than original reports suggest, and newer reversible substrate-specific MAOIs may offer even less toxicity. The author reviews the pharmacology, mechanism of action, clinical indications, and dosing strategies of MAOIs. The common MAOI side-effects (hypotension, weight gain, sexual dysfunction, insomnia, daytime sedation, myoclonus, and hypertensive episodes) are described and management techniques suggested. Recent clinical developments involving MAOIs are outlined.

Entities:  

Year:  1990        PMID: 21233984      PMCID: PMC2280482     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  39 in total

1.  Management of monoamine oxidase inhibitor-associated insomnia with trazodone.

Authors:  A A Nierenberg; P E Keck
Journal:  J Clin Psychopharmacol       Date:  1989-02       Impact factor: 3.153

Review 2.  Antidepressants in panic disorder and agoraphobia.

Authors:  R B Lydiard; J C Ballenger
Journal:  J Affect Disord       Date:  1987 Sep-Oct       Impact factor: 4.839

3.  Moclobemide, a new reversible MAO inhibitor--interaction with tyramine and tricyclic antidepressants in healthy volunteers and depressive patients.

Authors:  A Korn; H G Eichler; R Fischbach; S Gasic
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

Review 4.  Clinical pharmacology of monoamine oxidase inhibitors.

Authors:  K D McDaniel
Journal:  Clin Neuropharmacol       Date:  1986       Impact factor: 1.592

Review 5.  Weight gain with antidepressants and lithium.

Authors:  E J Garland; R A Remick; A P Zis
Journal:  J Clin Psychopharmacol       Date:  1988-10       Impact factor: 3.153

6.  Clinical pharmacology of phenelzine.

Authors:  D S Robinson; A Nies; C L Ravaris; J O Ives; D Bartlett
Journal:  Arch Gen Psychiatry       Date:  1978-05

7.  Treatment of MAOI hypertensive crisis with sublingual nifedipine.

Authors:  C Clary; E Schweizer
Journal:  J Clin Psychiatry       Date:  1987-06       Impact factor: 4.384

8.  A controlled study of a specific MAO A reversible inhibitor (R011-1163) and amitriptyline in depressive illness.

Authors:  T R Norman; D Ames; G D Burrows; B Davies
Journal:  J Affect Disord       Date:  1985 Jan-Feb       Impact factor: 4.839

9.  Phenelzine in social phobia.

Authors:  M R Liebowitz; A J Fyer; J M Gorman; R Campeas; A Levin
Journal:  J Clin Psychopharmacol       Date:  1986-04       Impact factor: 3.153

10.  Common side effects associated with monoamine oxidase inhibitors.

Authors:  R A Remick; C Froese; F D Keller
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1989       Impact factor: 5.067

View more
  4 in total

1.  Computational Analysis of Therapeutic Neuroadaptation to Chronic Antidepressant in a Model of the Monoaminergic Neurotransmitter and Stress Hormone Systems.

Authors:  Mariam B Camacho; Warut D Vijitbenjaronk; Thomas J Anastasio
Journal:  Front Pharmacol       Date:  2019-10-25       Impact factor: 5.810

2.  The trace amine theory of spontaneous hypertension as induced by classic monoamine oxidase inhibitors.

Authors:  Vincent Van den Eynde
Journal:  J Neural Transm (Vienna)       Date:  2021-08-09       Impact factor: 3.575

3.  Tryptamine serves as a proligand of the AhR transcriptional pathway whose activation is dependent of monoamine oxidases.

Authors:  Linda Vikström Bergander; Wen Cai; Bernward Klocke; Martin Seifert; Ingemar Pongratz
Journal:  Mol Endocrinol       Date:  2012-08-03

Review 4.  The Serotonin Syndrome: From Molecular Mechanisms to Clinical Practice.

Authors:  James Francescangeli; Kunal Karamchandani; Meghan Powell; Anthony Bonavia
Journal:  Int J Mol Sci       Date:  2019-05-09       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.